PCL, Inc. (241820.KQ)

KRW 610.0

(-2.4%)

Market Cap (In KRW)

36.09 Billion

Revenue (In KRW)

8.42 Billion

Net Income (In KRW)

-20.31 Billion

Avg. Volume

1.8 Million

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
537.0-4050.0
PE
-
EPS
-
Beta Value
0.061
ISIN
KR7241820000
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Ms. Soyeon Kim
Employee Count
-
Website
http://www.pclchip.com
Ipo Date
2017-02-23
Details
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.